The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. (Q38910154)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

title

The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Matteo Ferro

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Giuseppe Lucarelli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Sabrina Rossetti

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Ottavio De Cobelli

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Michele Caraglia

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Michele Aieta

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Gaetano Facchini

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Carlo Buonerba

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

author name string

Giuseppe Di Lorenzo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Sabino De Placido

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Davide Bosso

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Livio Puglia

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Piero Pignataro

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Ilaria Ascione

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Daniela Terracciano

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

Guru Sonpavde

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

language of work or name

English

0 references

publication date

27 July 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

19 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

cites work

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Efficacy of rituximab in gastric diffuse large B cell lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Combination of docetaxel and cetuximab for penile cancer: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Kidney cancer: overall survival is an unsuitable primary end point

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-A

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Sipuleucel-T for prostate cancer: the immunotherapy era has commenced

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Endoglin for targeted cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

The CD27-CD70 pathway and pathogenesis of autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14712598.2016.1216964

10.1080/14712598.2016.1216964

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27463642 AND SRC:MED&resulttype=core&format=json

19 March 2020

1 reference